The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Bogaard M, Strømme JM, Kidd SG, Johannessen B, Bakken AC, Lothe RA, Axcrona K, Skotheim RI, Axcrona U(2024) GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer Neoplasia, 55, 101023(in press) DOI 10.1016/j.neo.2024.101023, PubMed 38944914
Rødland GE, Temelie M, Eek Mariampillai A, Hauge S, Gilbert A, Chevalier F, Savu DI, Syljuåsen RG(2024) Potential Benefits of Combining Proton or Carbon Ion Therapy with DNA Damage Repair Inhibitors Cells, 13(12) DOI 10.3390/cells13121058, PubMed 38920686
Kurganovs NJ, Engedal N(2024) To eat or not to eat: a critical review on the role of autophagy in prostate carcinogenesis and prostate cancer therapeutics Front Pharmacol, 15, 1419806 DOI 10.3389/fphar.2024.1419806, PubMed 38910881
Bogaard M, Strømme JM, Kidd SG, Johannessen B, Bakken AC, Lothe RA, Axcrona K, Skotheim RI, Axcrona U(2024) GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer Neoplasia, 55, 101023(in press) DOI 10.1016/j.neo.2024.101023, PubMed 38944914
von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, McConnell K, Sindaco P, Müller TA, Pützer S, Klepzig H, Jungherz D, Dechow A, Wahnschaffe L, Giri AK, Kankainen M, Kuusanmäki H, Neubauer HA, Moriggl RH, Mazzeo P, Schmidt N, Koch R, Hallek MJ, Chebel A, Armisen Det al.(2024) Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated Apoptotic Responses Blood(in press) DOI 10.1182/blood.2023022884, PubMed 38941598
Narod SA, Gronwald J, Karlan B, Moller P, Huzarski T, Tung N, Aeilts A, Eisen A, Randall Armel S, Singer CF, Foulkes WD, Neuhausen SL, Olopade O, Pal T, Fruscio R, Metcalfe K, Raj R, Jacobson M, Sun P, Lubinski J, Kotsopoulos J(2024) Incidence of Peritoneal Cancer Following Oophorectomy among BRCA1 and BRCA2 Mutation Carriers J Natl Cancer Inst(in press) DOI 10.1093/jnci/djae151, PubMed 38937272